Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)

Core Insights - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is recognized as one of the 12 best genomics stocks to invest in [1] Group 1: Investment Activity - Cathie Wood's ARK Investment purchased 755,000 shares of Recursion Pharmaceuticals on December 19, 2025 [2] Group 2: Analyst Ratings and Market Potential - JPMorgan upgraded Recursion Pharmaceuticals from Neutral to Overweight, raising the price target from $10 to $11, citing the effectiveness of REC-4881 in treating familial adenomatous polyposis [3] - The addressable market for REC-4881 is larger than previously anticipated, with JPMorgan estimating a 60% chance of success and peak revenues exceeding $1 billion [4] - Early anti-tumor effectiveness of the CDK7 inhibitor REC-617 in platinum-resistant ovarian cancer has also been noted by JPMorgan [4] Group 3: Financial Forecast - The company has maintained its 2025 expense forecast at less than $450 million, excluding partnership inflows, and the 2026 forecast at less than $390 million [5] - Recursion Pharmaceuticals expects its cash position to support operations until the end of 2027 without requiring additional funding [5]